Literature DB >> 28374859

Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil.

R Lacchini1, J J Muniz1, Y T D A Nobre2, A J Cologna2, A C P Martins2, J E Tanus-Santos3.   

Abstract

Arginase 1 (ARG1) and arginase 2 (ARG2) compete with nitric oxide synthases for the substrate l-arginine. Here we aim to assess whether arginase 1 and 2 plasma levels, plasma arginase activity or genetic factors are associated with altered responsiveness to sildenafil. We studied 71 post-prostatectomy erectile dysfunction (ED) patients (PED group) and 72 clinical ED patients (CED). Patients responded to the International Index of Erectile Function questionnaire before and after the treatment. We found positive and negative correlations between plasma levels of arginase 1 and sildenafil responsiveness in the PED and CED groups, respectively. PED group also presented negative correlation between plasma arginase activity and sildenafil responsiveness. Sildenafil poor responders have shown higher plasma arginase activity in PED and higher arginase 1 levels on CED groups. In addition, variant genotypes for the rs2781659, rs2781667 and rs17599586 polymorphisms were associated with reduced arginase activity, as well as the GTTT ARG1 haplotype in CED group.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28374859     DOI: 10.1038/tpj.2017.2

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  46 in total

1.  Genetic variations in nitric oxide synthase and arginase influence exhaled nitric oxide levels in children.

Authors:  M T Salam; T M Bastain; E B Rappaport; T Islam; K Berhane; W J Gauderman; F D Gilliland
Journal:  Allergy       Date:  2010-10-06       Impact factor: 13.146

2.  Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity.

Authors:  Jiangning Yang; Adrian T Gonon; Per-Ove Sjöquist; Jon O Lundberg; John Pernow
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

3.  Kinetics of the utilization of dietary arginine for nitric oxide and urea synthesis: insight into the arginine-nitric oxide metabolic system in humans.

Authors:  François Mariotti; Klaus J Petzke; Damien Bonnet; Isabelle Szezepanski; Cécile Bos; Jean-François Huneau; Hélène Fouillet
Journal:  Am J Clin Nutr       Date:  2013-03-27       Impact factor: 7.045

Review 4.  Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?

Authors:  Georgios Bouras; Spyridon Deftereos; Dimitrios Tousoulis; Georgios Giannopoulos; Georgios Chatzis; Dimitrios Tsounis; Michael W Cleman; Christodoulos Stefanadis
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice.

Authors:  Haroldo A Toque; Maritza J Romero; Rita C Tostes; Alia Shatanawi; Surabhi Chandra; Zidonia N Carneiro; Edward W Inscho; Robert Clinton Webb; Ruth B Caldwell; Robert William Caldwell
Journal:  J Sex Med       Date:  2010-08-30       Impact factor: 3.802

6.  Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats.

Authors:  Robert Segal; Johanna L Hannan; Xiaopu Liu; Omer Kutlu; Arthur L Burnett; Hunter C Champion; Jae Hyung Kim; Jochen Steppan; Dan E Berkowitz; Trinity J Bivalacqua
Journal:  J Androl       Date:  2012-04-05

7.  ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.

Authors:  Augusto A Litonjua; Jessica Lasky-Su; Kady Schneiter; Kelan G Tantisira; Ross Lazarus; Barbara Klanderman; John J Lima; Charles G Irvin; Stephen P Peters; John P Hanrahan; Stephen B Liggett; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Christoph Lange; Scott T Weiss
Journal:  Am J Respir Crit Care Med       Date:  2008-07-10       Impact factor: 21.405

8.  Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness.

Authors:  Julie Dumont; Mahmoud Zureik; Dominique Cottel; Michèle Montaye; Pierre Ducimetière; Philippe Amouyel; Thierry Brousseau
Journal:  J Med Genet       Date:  2007-03-16       Impact factor: 6.318

9.  Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction.

Authors:  Riccardo Lacchini; Jaqueline J Muniz; Yuri T D A Nobre; Adauto J Cologna; Antonio C P Martins; Jose E Tanus-Santos
Journal:  Nitric Oxide       Date:  2015-11-07       Impact factor: 4.427

Review 10.  Pharmacogenetics of erectile dysfunction: navigating into uncharted waters.

Authors:  Riccardo Lacchini; Jose E Tanus-Santos
Journal:  Pharmacogenomics       Date:  2014-08       Impact factor: 2.533

View more
  3 in total

1.  Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Authors:  Abdel Shakour Abdel Hafez Abdel Wahed; Mohamed Abdel Mawgood Amer; Nagah Mohamed Abou Mohamed; Mohamed Ismael Mobasher; Hassan Mamdouh; Sameh Fayek GamalEl Din; Mohammed Said ElSheemy
Journal:  Int Urol Nephrol       Date:  2018-06-28       Impact factor: 2.370

2.  Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

Authors:  Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

3.  Association analysis between ARG1 gene polymorphisms and idiopathic dilated cardiomyopathy.

Authors:  Syed Fawad Ali Shah; Sumaira Akram; Tahir Iqbal; Sadia Nawaz; Muhammad Arshad Rafiq; Sabir Hussain
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.